WO2021205214A1 - System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19) - Google Patents

System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19) Download PDF

Info

Publication number
WO2021205214A1
WO2021205214A1 PCT/IB2020/053415 IB2020053415W WO2021205214A1 WO 2021205214 A1 WO2021205214 A1 WO 2021205214A1 IB 2020053415 W IB2020053415 W IB 2020053415W WO 2021205214 A1 WO2021205214 A1 WO 2021205214A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
icue
signal generator
ultrasound
intensity
Prior art date
Application number
PCT/IB2020/053415
Other languages
French (fr)
Inventor
Gunnar Myhr
Original Assignee
Modi Vivendi As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modi Vivendi As filed Critical Modi Vivendi As
Priority to PCT/IB2020/053415 priority Critical patent/WO2021205214A1/en
Priority to NO20200436A priority patent/NO20200436A1/en
Publication of WO2021205214A1 publication Critical patent/WO2021205214A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/44Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/46Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/52Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/5215Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
    • A61B8/5223Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for extracting a diagnostic or physiological parameter from medical diagnostic data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N2007/0004Applications of ultrasound therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N2007/0039Ultrasound therapy using microbubbles

Definitions

  • the present invention relates to systems and optimized procedures for non-invasive removal of fluids in the lungs, bronchial and alveolar organs by the application of ultrasound.
  • WO2018126322 provides an apparatus, method, and use for ultrasound mediated micro bubble delivery of pharmaceutically active molecule(s) to the pulmonary tissue.
  • WO2017126753 describes an apparatus to which the ultrasound probe is connected, and a server connected to the ultrasound monitoring apparatus, wherein a B-line of the lungs is measured by the ultrasound probe and the ultrasound monitoring apparatus, enabling to monitor the state of the lungs of intensive care patients.
  • US2011142837 provides methods for treating and/or alleviating acute respiratory distress syndrome in an individual.
  • the methods comprise administering a therapeutically effective amount of a complement thereby treating the ARDS, or delaying or preventing onset of ARDS.
  • US2015068526 describes a ventilator for use by a clinician in supporting a patient presenting pulmonary distress.
  • a controller operates a positive or negative pressure gas source that communicates with the intubated or negative pressure configured patient through valved supply and exhaust ports.
  • COVID-19 resemble those of SARS and MERS.
  • the early stages of an infection reveal the presence of pneumonia, edema, proteinaceous exudate with globules and focal hyperplasia of alveolar epithelial cells associated with patchy inflammatory infiltrates.
  • DAD diffuse alveolar damage
  • An objective of the present invention is to provide an ultrasound system and method for non-invasive removal of fluids in the lungs, bronchial and alveolar organs by the application of ultrasound.
  • the system includes a processing unit (1), an ultrasound signal generator (2), ultrasound probe(s) (3), and Intensive Care Unit Equipment - ICUE (5).
  • the processor (1) includes a memory and runs a program stored in the memory causing the system to perform steps of measuring and/or monitoring input parameters from the ICUE (5) and/or controlling devices represented by the ICUE (5).
  • the system is suitable for Machine learning and/or Artificial Intelligence. One preferred application is to treat patients infected with the SARS-CoV-2 virus and the subsequent disease COVID-19.
  • alveolar has typically a diameter of 200 pm.
  • alveoli and/or bronchial tracts come in, one or several modes related to harmonic vibrations, reach one of several natural frequencies, being exposed to pressure waves or shear waves, of a system of such organs, thus displacing alveoli and/or bronchial fluids.
  • ICUE (5) represents a group of electronic, electric, and mechanical quipment and devices that are locally or remotely connected together to monitor and control a target environment, i.e., a patient (4). In this application, this represents to monitor the restoring of an adequate respiratory capability of the patient.
  • Real-time control system means that the control system must provide the control responses or actions to the stimulus or requests within specific times, which therefore depend not just on what the system does but also on how fast it reacts.
  • each of the stimulus handlers requires aprocess (or task).
  • a real-time control system normally consists of these three types of processes: (1) Sensor control processes that collect information from sensors and may buffer information collected in response to a sensor stimulus. (2) Data processor carrying out processing of collected information and computing the system response. (3) Actuator control processes that generate control signals for actuators.
  • Real-time control systems are usually designed in the software as cooperating processes with an executive concurrently controlling of these processes. (Industrial control technology; a handbook for engineers and researchers, Peng Zhang, William Andrew Inc, 2008.)
  • the provided systems can have forecasting, self-learning and/or intelligent capabilities.
  • Machine learning is a way of development which enables an algorithm to evolve.
  • “learning” means feeding the algorithm with a massive amount of data so that it can adjust itself and continually improve.
  • AI Artificial Intelligence
  • An intensive care unit also known as an intensive therapy unit or intensive treatment unit (ITU) or critical care unit (CCU) is a special department of a hospital or health care facility that provides intensive treatment medicine.
  • Intensive care unit equipment includes, but are not limited to, patient monitoring, life support and emergency resuscitation devices, and diagnostic devices.
  • Intensive care equipment for life support and emergency resuscitation includes in this context, but are not limited to, the following: acute care physiologic monitoring system, i.e., comprehensive patient monitoring systems that can be configured to continuously measure and display a number of parameters via electrodes and sensors that are connected to the patient (these may include the electrical activity of the heart via an EKG, respiration rate, blood pressure, body temperature, cardiac output, amount of O2 and CO2 in the blood), pulse oximeter, which monitors the arterial hemoglobin oxygen saturation of the patient's blood with a sensor clipped over the finger or toe, an intracranial pressure monitor that measures the pressure of fluid in the brain in patients with head trauma or other conditions affecting the brain (such as tumors, edema, or hemorrhage) (these devices warn of elevated pressure and record or display pressure trends), an apnea monitor, which continuously monitors breathing via electrodes or sensors placed on the patient, ventilators (respirators) which regulate the volume, pressure, and flow of patient respiration (ventilator
  • suction catheter and suction machines or aspirators which are tracheostomy-care devices used for removing obstructions from a person's airway using suction to pull out mucus, saliva, blood, secretions or other fluids clearing the airway (See e.g.:https://dir.indiamart.com/impcat/suction-machine.html, and https://www.healthproductsforyou.com/c-suction-machinesaspirators.html).
  • the ICUE (5) includes at least one of the above listed features, elements or functionalities.
  • An ultrasound signal generator (2) provides energy to an ultrasound transmitter (3).
  • the ultrasound transmitter may be combinations of single transducers, an array of transducers or a phase array of transducers.
  • Single transducers may be focused by shaping the transducer.
  • Arrays of transducers allow beam forming and focusing techniques.
  • the arrays and elements can be of a general type, for example annular arrays, phased or switched arrays, matrix arrays, linear arrays with division in both azimuth and elevation direction.
  • the at least one transducer can transmit at least one therapy beam based on at least one set of transmit parameters, where said transmit parameters comprises at least one of i) a transmit focus, ii) a transmit frequency, iii) a transmit pulse amplitude, iv) a transmit pulse length, v) a transmit pulse repetition frequency, vi) a treatment beam transmit duration.
  • the signal generator sets up the transmit parameters and the transducer transmits the at least one therapy beam across the region of the body (thorax) to be treated.
  • Fig. 1 is a cross sectional view showing a normal alveolus on the left side and an injured alveolus suffering acute respiratory distress syndrome on the right side;
  • Fig. 2 is a block diagram of a system according to an embodiment of the present invention.
  • a system includes processing unit (1), which may include ML and/or AI, provides input to a signal generator (2), which provide a frequency signal and energy input to a transducer assembly, i.e., an ultrasound probe (3) having at least one transducer.
  • a transducer assembly i.e., an ultrasound probe (3) having at least one transducer.
  • the at least one transducer can be attached with a fluid or gel padding (not shown) to maximize acoustic contact.
  • a gel can be added between the patient and the padding.
  • the ultrasound probe (3) can be placed on the chest or the back of the patient (4), but not necessarily.
  • the input signal from the generator (2) to the at least one transducer of the ultrasound probe (3) can represent combinations of a fixed or variable energy intensity and a fixed or variable frequency.
  • the system also includes Intensive Care Unit Equipment (ICUE) (5) a group of electronic, electric, and mechanical equipment and devices that are locally or remotely connected together to monitor and control a target environment of a patient (4).
  • the energy intensity level I meets the following: 0 ⁇ I ⁇ 500 W/cm 2 , preferably in the range: 0 ⁇ I ⁇ 25 W/cm 2 .
  • Pulse duration, if applied, is 1 to 5000 cycles.
  • thermocouple sensors can be incorporated with a suction catheter, by a separate probe for insertion into the airway, placed on (outside) the body (e.g. chest or combinations of these modes). Temperature sensors are an integral part of the ICUE (5).
  • the ICUE (5) measures and monitors in real time, preferable, but not limited to, the amount of O2 and CO2 in the blood.
  • the increase of O2 and/or decrease of CO2 in the blood, positive changes in respiratory rate, cardiac activity or any other parameters measured by the ICUE (5), is interpreted as a drainage of fluid in the alveolar and/or bronchial system, thus providing increased O2 influx over the alveolar membrane.
  • the processing unit (1) with input from the ICUE (5) can adjust the signal generator
  • the processing unit (1) will send a command to the signal generator (2) to reduce the intensity from the at least one transducer
  • the at least one transducer of the ultrasound probe is subject to active cooling by an appropriate medium.
  • the active cooling can be controlled in response to the temperature in the airway, lung/bronchial or alveoli system of the patient (4) or in response to a temperature of the ultrasound probe (3).
  • the output signal from the processing unit (1) can be manually fixed, thus overriding the closed feedback or the intelligence of the system.
  • the processing unit (1) can include ML and/or AI capabilities, thus the system (1-5) can evolve as a function of time and according to the improvements of the patient(s).
  • a pharmaceutical substance is a substance (including a mixture or compound of substances) for therapeutic use whose application involves a chemical interaction and/or a physicochemical interaction with a human physiological system.
  • Micro bubbles are small spherical type of bubbles which consists of a gas. They have a size range usually in the range 1-100 micrometer. They are capable of penetrating even into the smallest blood capillaries and releasing drugs or genes, incorporated on their surface, under the action of ultrasound, International Journal of Pharmaceutical Sciences and Research 20(3):3058-3063, 2012.”
  • the system (1-5) can be operated in conjunction with pharmaceutical substances and/or micro bubbles which are injected into the patient.
  • a system for providing acoustic energy into a human body includes a processing unit (1), an ultrasound signal generator (2), an ultrasound probe (3), and an ICUE (5).
  • the processor (1) includes a memory, and the processor (1) runs a program stored in the memory causing the system to perform the steps of: providing input signals to the signal generator (2) and ultrasound probe (3), the processor (1) running the program stored in the memory further causes the system to perform the steps of: measuring and/or monitoring input parameters from the ICUE (5) unit and/or controlling units represented by the ICUE (5) represented by: activity of the heart, respiratory rate, blood pressure, body temperature, cardiac output, amount of O2 and CO2 in the blood, the arterial hemoglobin oxygen saturation of the patient's blood, the pressure of fluid in the brain, ventilators (respirators), infusion pumps, intraaortic balloon pump, suction catheter(s) and suction machines, and temperature measurements of the thorax/lung/bronchial/ alveoli system.

Abstract

A system for providing acoustic energy into a human body includes a processing unit with a processor and a memory, an ultrasound signal generator, an ultrasound probe having at least one transducer, the ultrasound signal generator generating actuating signals for the at least one transducer, and intensive care unit equipment (ICUE) including equipment and devices that are locally or remotely connected together to monitor and control a target environment of a patient, in real time. The processor runs a program stored in the memory and causes the system to perform the steps providing input signals to the signal generator causing the signal generator to actuate the ultrasound probe to transmit an ultrasound beam to the patient at a frequency and intensity that remove fluid from alveoli in a lung of the patient; and monitoring, by the ICUE, parameters of the patient or equipment connected to the patient, including real time temperature measurements within the airway, and lung/bronchial or alveoli system(s).

Description

SYSTEM AND METHOD FOR THE REMOVAL OF ALVEOLAR (THORAX) FLUIDS IN PATIENTS WITH INFECTIOUS AND/OR VIRUS DISEASES (COVID-19)
Field of the Invention
The present invention relates to systems and optimized procedures for non-invasive removal of fluids in the lungs, bronchial and alveolar organs by the application of ultrasound.
Background of the Invention
WO2018126322 provides an apparatus, method, and use for ultrasound mediated micro bubble delivery of pharmaceutically active molecule(s) to the pulmonary tissue.
WO2017126753 describes an apparatus to which the ultrasound probe is connected, and a server connected to the ultrasound monitoring apparatus, wherein a B-line of the lungs is measured by the ultrasound probe and the ultrasound monitoring apparatus, enabling to monitor the state of the lungs of intensive care patients.
US2011142837 provides methods for treating and/or alleviating acute respiratory distress syndrome in an individual. The methods comprise administering a therapeutically effective amount of a complement thereby treating the ARDS, or delaying or preventing onset of ARDS.
US2015068526 describes a ventilator for use by a clinician in supporting a patient presenting pulmonary distress. A controller operates a positive or negative pressure gas source that communicates with the intubated or negative pressure configured patient through valved supply and exhaust ports.
Patients with preexisting diseases such as, for example, diabetes, chronic obstructive pulmonary disease (CORP), kidney dysfunctions, coronary heart disease have worst clinical outcomes when infected with the virus SARS-CoV-2. The only current treatment of the subsequent disease COVID-19 is supportive.
The pathological features of COVID-19 resemble those of SARS and MERS. The early stages of an infection reveal the presence of pneumonia, edema, proteinaceous exudate with globules and focal hyperplasia of alveolar epithelial cells associated with patchy inflammatory infiltrates. At later stages, diffuse alveolar damage (DAD) is observed in addition to hemorrhage and some areas of interstitial fibrosis. https://journals.physiology.org/doi/pdf/10.1152/physrev.00013.2020 (Physiol Rev 100:1065- 1075, 2020) Lethality of Covid-19 is critically driven by disruption of the alveolar-capillary barrier of the lung, leading to lung edema as a direct consequence of SARS-CoV-2 infection, and/or cause acute respiratory distress syndrome (ARDS). See fig. 1 for an illustration of alveolar edema and ARDS https ://papers. ssrn.com/sol3/papers. cfm?abstract_id=3558887
Successful drainage of alveolar fluids can restore the alveolar-capillary barrier and provide adequate O2 and CO2 exchange, thus reduce COVID-19 lethality.
Brief Summary of the Invention
An objective of the present invention is to provide an ultrasound system and method for non-invasive removal of fluids in the lungs, bronchial and alveolar organs by the application of ultrasound.
According to an embodiment of the invention, the system includes a processing unit (1), an ultrasound signal generator (2), ultrasound probe(s) (3), and Intensive Care Unit Equipment - ICUE (5). The processor (1) includes a memory and runs a program stored in the memory causing the system to perform steps of measuring and/or monitoring input parameters from the ICUE (5) and/or controlling devices represented by the ICUE (5). The system is suitable for Machine learning and/or Artificial Intelligence. One preferred application is to treat patients infected with the SARS-CoV-2 virus and the subsequent disease COVID-19.
An alveolar has typically a diameter of 200 pm. By applying the right frequencies and adequate ultrasound energy intensity, alveoli and/or bronchial tracts come in, one or several modes related to harmonic vibrations, reach one of several natural frequencies, being exposed to pressure waves or shear waves, of a system of such organs, thus displacing alveoli and/or bronchial fluids.
The system operates in real time or in an approximate real time modus. ICUE (5) represents a group of electronic, electric, and mechanical quipment and devices that are locally or remotely connected together to monitor and control a target environment, i.e., a patient (4). In this application, this represents to monitor the restoring of an adequate respiratory capability of the patient.
In general, the target environment is inevitably associated with hardware devices that are sensors, actuators, and valves. Real-time control system means that the control system must provide the control responses or actions to the stimulus or requests within specific times, which therefore depend not just on what the system does but also on how fast it reacts. In software, each of the stimulus handlers requires aprocess (or task). A real-time control system normally consists of these three types of processes: (1) Sensor control processes that collect information from sensors and may buffer information collected in response to a sensor stimulus. (2) Data processor carrying out processing of collected information and computing the system response. (3) Actuator control processes that generate control signals for actuators. Real-time control systems are usually designed in the software as cooperating processes with an executive concurrently controlling of these processes. (Industrial control technology; a handbook for engineers and researchers, Peng Zhang, William Andrew Inc, 2008.)
The provided systems can have forecasting, self-learning and/or intelligent capabilities. Machine learning (ML) is a way of development which enables an algorithm to evolve. In this case “learning” means feeding the algorithm with a massive amount of data so that it can adjust itself and continually improve.
Artificial Intelligence (AI) is linked to the concept of mimicking human decision making processes, and the performance of complex tasks in a more human-like way.
It involves machines that have the ability to carry out tasks characteristic of human intelligence. It’s a much broader concept than machine learning. These tasks include: planning, problem-solving, learning, and can include understanding languages and to recognize voices and images. Some relevant IA languages or platforms are; Python, R, Wolfram Language and MATLAB.
An intensive care unit (ICU), also known as an intensive therapy unit or intensive treatment unit (ITU) or critical care unit (CCU), is a special department of a hospital or health care facility that provides intensive treatment medicine. Intensive care unit equipment includes, but are not limited to, patient monitoring, life support and emergency resuscitation devices, and diagnostic devices. Intensive care equipment for life support and emergency resuscitation includes in this context, but are not limited to, the following: acute care physiologic monitoring system, i.e., comprehensive patient monitoring systems that can be configured to continuously measure and display a number of parameters via electrodes and sensors that are connected to the patient (these may include the electrical activity of the heart via an EKG, respiration rate, blood pressure, body temperature, cardiac output, amount of O2 and CO2 in the blood), pulse oximeter, which monitors the arterial hemoglobin oxygen saturation of the patient's blood with a sensor clipped over the finger or toe, an intracranial pressure monitor that measures the pressure of fluid in the brain in patients with head trauma or other conditions affecting the brain (such as tumors, edema, or hemorrhage) (these devices warn of elevated pressure and record or display pressure trends), an apnea monitor, which continuously monitors breathing via electrodes or sensors placed on the patient, ventilators (respirators) which regulate the volume, pressure, and flow of patient respiration (ventilator monitors and alarms may interface with a central monitoring system or information system), infusion pumps that deliver fluids intravenously or epidurally through a catheter (infusion pumps employ automatic, programmable pumping mechanisms to deliver continuous anesthesia, drugs, and blood infusions to the patient), resuscitation or code cart containing emergency resuscitation equipment for patients who are "coding", i.e., their vital signs are in a dangerous range (the emergency equipment includes a defibrillator, airway intubation devices, a resuscitation bag/mask, and medication box), intraaortic balloon pump that helps reduce the heart's workload and helps blood flow to the coronary arteries for patients with unstable angina, myocardial infarction (heart attack), or patients awaiting organ transplants (intraaortic balloon pumps use a balloon placed in the patient's aorta, the balloon being arranged on the end of a catheter that is connected to the pump's console, which displays heart rate, pressure, and electrocardiogram (ECG) readings (https://www.surgeryencyclopedia.com/Fi-La/Intensive-Care-Unit-Equipment.html, See also e.g. https://adonyss.com and https://www.narang-usa.com)), a suction catheter and suction machines or aspirators, which are tracheostomy-care devices used for removing obstructions from a person's airway using suction to pull out mucus, saliva, blood, secretions or other fluids clearing the airway (See e.g.:https://dir.indiamart.com/impcat/suction-machine.html, and https://www.healthproductsforyou.com/c-suction-machinesaspirators.html).
The ICUE (5) includes at least one of the above listed features, elements or functionalities.
An ultrasound signal generator (2) provides energy to an ultrasound transmitter (3). The ultrasound transmitter may be combinations of single transducers, an array of transducers or a phase array of transducers. Single transducers may be focused by shaping the transducer. Arrays of transducers allow beam forming and focusing techniques. The arrays and elements can be of a general type, for example annular arrays, phased or switched arrays, matrix arrays, linear arrays with division in both azimuth and elevation direction.
The at least one transducer can transmit at least one therapy beam based on at least one set of transmit parameters, where said transmit parameters comprises at least one of i) a transmit focus, ii) a transmit frequency, iii) a transmit pulse amplitude, iv) a transmit pulse length, v) a transmit pulse repetition frequency, vi) a treatment beam transmit duration. The signal generator sets up the transmit parameters and the transducer transmits the at least one therapy beam across the region of the body (thorax) to be treated.
Other objects and features of the present invention will become apparent from the following detailed description considered in conjunction with the accompanying drawings. It is to be understood, however, that the drawings are designed solely for purposes of illustration and not as a definition of the limits of the invention, for which reference should be made to the appended claims. It should be further understood that the drawings are not necessarily drawn to scale and that, unless otherwise indicated, they are merely intended to conceptually illustrate the structures and procedures described herein.
Brief Description of the Drawings
In the drawings:
Fig. 1 is a cross sectional view showing a normal alveolus on the left side and an injured alveolus suffering acute respiratory distress syndrome on the right side; and
Fig. 2 is a block diagram of a system according to an embodiment of the present invention; and
Preferred embodiments of the invention
A system according to an embodiment of the present invention includes processing unit (1), which may include ML and/or AI, provides input to a signal generator (2), which provide a frequency signal and energy input to a transducer assembly, i.e., an ultrasound probe (3) having at least one transducer. The at least one transducer can be attached with a fluid or gel padding (not shown) to maximize acoustic contact. A gel can be added between the patient and the padding. The ultrasound probe (3) can be placed on the chest or the back of the patient (4), but not necessarily. The input signal from the generator (2) to the at least one transducer of the ultrasound probe (3) can represent combinations of a fixed or variable energy intensity and a fixed or variable frequency. The system also includes Intensive Care Unit Equipment (ICUE) (5) a group of electronic, electric, and mechanical equipment and devices that are locally or remotely connected together to monitor and control a target environment of a patient (4).
The energy intensity level I meets the following: 0 < I <500 W/cm2, preferably in the range: 0 < I <25 W/cm2. The frequencies f: 0< f < 15 MHz, preferably in the range: 0< f < 500 kHz.
Pulse duration, if applied, is 1 to 5000 cycles.
To prevent excess heating in thorax/lung system/alveoli, human thermocouple or temperature sensors could be applied. The thermocouple sensors can be incorporated with a suction catheter, by a separate probe for insertion into the airway, placed on (outside) the body (e.g. chest or combinations of these modes). Temperature sensors are an integral part of the ICUE (5).
The ICUE (5) measures and monitors in real time, preferable, but not limited to, the amount of O2 and CO2 in the blood. The increase of O2 and/or decrease of CO2 in the blood, positive changes in respiratory rate, cardiac activity or any other parameters measured by the ICUE (5), is interpreted as a drainage of fluid in the alveolar and/or bronchial system, thus providing increased O2 influx over the alveolar membrane.
The processing unit (1), with input from the ICUE (5) can adjust the signal generator
(2) to control the at least one transducer of the ultrasound probe (3) to provide a combination of a fixed or variable energy intensity and a fixed or variable frequency which maximized the increase of O2 and/or decrease of CO2 in the blood.
If the temperature in the airway, lung/bronchial or alveoli system of the patient (4) exceeds a predetermined level, e.g., 41 degrees Celsius, the processing unit (1) will send a command to the signal generator (2) to reduce the intensity from the at least one transducer
(3), ensuring the temperature within the airway, lung/bronchial or alveoli system stays at or below the maximum predetermined temperature level. In addition, the at least one transducer of the ultrasound probe is subject to active cooling by an appropriate medium. The active cooling can be controlled in response to the temperature in the airway, lung/bronchial or alveoli system of the patient (4) or in response to a temperature of the ultrasound probe (3).
The output signal from the processing unit (1) can be manually fixed, thus overriding the closed feedback or the intelligence of the system.
The processing unit (1) can include ML and/or AI capabilities, thus the system (1-5) can evolve as a function of time and according to the improvements of the patient(s).
A pharmaceutical substance is a substance (including a mixture or compound of substances) for therapeutic use whose application involves a chemical interaction and/or a physicochemical interaction with a human physiological system.
Micro bubbles are small spherical type of bubbles which consists of a gas. They have a size range usually in the range 1-100 micrometer. They are capable of penetrating even into the smallest blood capillaries and releasing drugs or genes, incorporated on their surface, under the action of ultrasound, International Journal of Pharmaceutical Sciences and Research 20(3):3058-3063, 2012.”
The system (1-5) can be operated in conjunction with pharmaceutical substances and/or micro bubbles which are injected into the patient.
In preferred embodiments a system for providing acoustic energy into a human body includes a processing unit (1), an ultrasound signal generator (2), an ultrasound probe (3), and an ICUE (5). The processor (1) includes a memory, and the processor (1) runs a program stored in the memory causing the system to perform the steps of: providing input signals to the signal generator (2) and ultrasound probe (3), the processor (1) running the program stored in the memory further causes the system to perform the steps of: measuring and/or monitoring input parameters from the ICUE (5) unit and/or controlling units represented by the ICUE (5) represented by: activity of the heart, respiratory rate, blood pressure, body temperature, cardiac output, amount of O2 and CO2 in the blood, the arterial hemoglobin oxygen saturation of the patient's blood, the pressure of fluid in the brain, ventilators (respirators), infusion pumps, intraaortic balloon pump, suction catheter(s) and suction machines, and temperature measurements of the thorax/lung/bronchial/ alveoli system.
The present invention is not limited to the described apparatus, system or algorithms, thus all devices and the use thereof that are functionally equivalent are included by the scope of the invention. Modifications of the patent clai are within the scope of the invention.
Drawings and figures are to be interpreted illustratively and not in a limiting context. It is further presupposed that all the clai shall be interpreted to cover all generic and specific characteristics of the invention which are described, and that all aspects related to the invention, no matter the specific use of language, shall be included. Thus, the whole document and the stated references have to be interpreted to be included as part of this invention’s basis, methodology, mode of operation and apparatus or system.

Claims

CLAIMS What is claimed is:
1. A system for providing acoustic energy into a human body, the system comprising: a processing unit including a processor and a memory, a ultrasound signal generator, an ultrasound probe having at least one transducer, the ultrasound signal generator generating actuating signals for the at least one transducer, intensive care unit equipment (ICUE) including equipment and devices that monitor and control a target environment of a patient, wherein the processor, running a program stored in the memory, causes the system to perform the following steps: actuating, by the signal generator, the ultrasound probe to transmit an ultrasound beam to the patient at a frequency and intensity that remove fluid from alveoli in a lung of the patient; monitoring, by the ICUE, parameters of the patient or equipment connected to the patient; and determining, by the processing unit, whether the ultrasound beam produces a drainage of fluid in the alveolar and/or bronchial system based on the parameters monitored by the ICUE.
2. The system of claim 1, wherein the processor further performs the step of: controlling equipment of the ICUE.
3. The system of claim 1, wherein the processor further performs the step of: adjusting the input signals to the signal generator based on the parameters monitored by the ICUE.
4. The system of claim 3, wherein the parameters relate to at least one parameter of the group consisting of activity of the heart, respiratory rate, blood pressure, body temperature, cardiac output, amount of O2 and CO2 in the blood, the arterial hemoglobin oxygen saturation of the patient's blood, the pressure of fluid in the brain, ventilators (respirators), infusion pumps, intraaortic balloon pump, suction catheter(s) and suction machines, temperature measurements within the airway, and lung/bronchial or alveoli system(s).
5. The system of claim 1, wherein the intensity is in the range including 0 to 500 W/cm2.
6. The system of claim 5, wherein the intensity is in the range including 0 to 25 W/cm2.
7. The system of claim 1, wherein the frequency is in the range including 0 to 15 MHz.
8. The system of claim 7, wherein the frequency is in the range including 0 to 500 kHz.
9. The system of claim 3, wherein the adjusting includes lowering the intensity of the ultrasound beam when a temperature of in an airway, a lung, a bronchial system or an alveoli system of the patientexceeds a predetermined threshold.
10. The system of claim 1, wherein the processor further performs the steps of adjusting at least one of frequency and intensity of the ultrasound beam until the parameters monitored by the ICUE indicate an improvement in respiratory function.
11. The system of claim 10, wherein the processor has AI or ML capabilities and further performs the step of: learning effective treatment parameters by storing intensity and frequency levels that results in the improvement in respiratory function.
12. The system of claim 1, wherein operated in conjunction with pharmaceutical substances and/or micro bubbles which are injected into the patient.
13. A method for providing acoustic energy into a human body, the method comprising: providing, by a processor, input signals to a signal generator causing the signal generator to actuate at least one transducer of an ultrasound probe to transmit an ultrasound beam to a patient at a frequency and intensity that remove fluid from alveoli in a lung of the patient; monitoring, by an ICUE, parameters of the patient or equipment connected to the patient, the ICUE including equipment and devices that are locally or remotely connected together to monitor and control a target environment of the patient; and determining, by the processing unit, whether the ultrasound beam produces a drainage of fluid in the alveolar and/or bronchial system based on the parameters monitored by the ICUE.
14. The method of claim 13, further comprising the step of: adjusting the input signals to the signal generator based on the parameters monitored by the ICUE.
15. The method of claim 14, wherein the parameters relate to at least one parameter of the group consisting of activity of the heart, respiratory rate, blood pressure, body temperature, cardiac output, amount of O2 and CO2 in the blood, the arterial hemoglobin oxygen saturation of the patient's blood, the pressure of fluid in the brain, ventilators (respirators), infusion pumps, intraaortic balloon pump, suction catheter(s) and suction machines, temperature measurements within the airway, and lung/bronchial or alveoli system(s).
16. The method of claim 14, wherein the step of adjusting includes lowering the intensity of the ultrasound beam when a temperature of in an airway, a lung, a bronchial system or an alveoli system of the patient exceeds a predetermined threshold.
17. The method of claim 13, further comprising the step of adjusting at least one of frequency and intensity of the ultrasound beam until the parameters monitored by the ICUE indicate an improvement in respiratory function.
18. The method of claim 17, wherein the processor has AI or ML capabilities and the method further comprises the step of: learning effective treatment parameters by storing intensity and frequency levels that results in the improvement in respiratory function.
19. The method of claim 1, wherein the step of providing input signals is performed in conjunction with the injection of pharmaceutical substances and/or micro bubbles into the patient.
PCT/IB2020/053415 2020-04-09 2020-04-09 System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19) WO2021205214A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2020/053415 WO2021205214A1 (en) 2020-04-09 2020-04-09 System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19)
NO20200436A NO20200436A1 (en) 2020-04-09 2020-04-10 System and method for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/053415 WO2021205214A1 (en) 2020-04-09 2020-04-09 System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19)

Publications (1)

Publication Number Publication Date
WO2021205214A1 true WO2021205214A1 (en) 2021-10-14

Family

ID=70293021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/053415 WO2021205214A1 (en) 2020-04-09 2020-04-09 System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19)

Country Status (2)

Country Link
NO (1) NO20200436A1 (en)
WO (1) WO2021205214A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402103C (en) * 2003-05-22 2008-07-16 重庆海扶(Hifu)技术有限公司 Fluid discharging aerating breathing system
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US20150068526A1 (en) 2007-06-01 2015-03-12 Intensive Care Online Network, Inc. Ventilator Apparatus and System of Ventilation
WO2017126753A1 (en) 2016-01-21 2017-07-27 서울대학교병원 (분사무소) Ultrasound system and monitoring method for continuous monitoring of state of the lungs
WO2018126322A1 (en) 2017-01-05 2018-07-12 Warren Lee Apparatus, method, and use for ultrasound mediated microbubble delivery of pharmaceutical compositions
WO2019240665A1 (en) * 2018-06-14 2019-12-19 Bark Technology Pte. Ltd. Vibroacoustic device and method for treating restrictive pulmonary diseases and improving drainage function of lungs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221323B2 (en) * 2007-08-03 2012-07-17 Cardiac Pacemakers, Inc. Using acoustic energy to compute a lung edema fluid status indication
WO2015038886A1 (en) * 2013-09-12 2015-03-19 Holaira, Inc. Systems, devices, and methods for treating a pulmonary disease with ultrasound energy
WO2017087824A1 (en) * 2015-11-19 2017-05-26 Dymedso, Inc. Systems, devices, and methods for pulmonary treatment
US11446004B2 (en) * 2017-06-09 2022-09-20 Tokitae Llc Ultrasound systems and methods of identifying fluids in body regions using the same
WO2019094802A1 (en) * 2017-11-09 2019-05-16 Montefiore Medical Center Low energy immune priming for treating cancer and metastasis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402103C (en) * 2003-05-22 2008-07-16 重庆海扶(Hifu)技术有限公司 Fluid discharging aerating breathing system
US20150068526A1 (en) 2007-06-01 2015-03-12 Intensive Care Online Network, Inc. Ventilator Apparatus and System of Ventilation
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
WO2017126753A1 (en) 2016-01-21 2017-07-27 서울대학교병원 (분사무소) Ultrasound system and monitoring method for continuous monitoring of state of the lungs
WO2018126322A1 (en) 2017-01-05 2018-07-12 Warren Lee Apparatus, method, and use for ultrasound mediated microbubble delivery of pharmaceutical compositions
WO2019240665A1 (en) * 2018-06-14 2019-12-19 Bark Technology Pte. Ltd. Vibroacoustic device and method for treating restrictive pulmonary diseases and improving drainage function of lungs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCESCO PRADA ET AL: "Can Low-Intensity Pulsed UltrasoundTreat Discrete Pulmonary Lesions inPatients With COVID-19?", JOURNAL OF ULTRASOUND IN MEDICINE., 19 October 2020 (2020-10-19), United States, XP055759203, ISSN: 0278-4297, DOI: 10.1002/jum.15522 *
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 20, no. 3, 2012, pages 3058 - 3063
PENG ZHANG: "a handbook for engineers and researchers", 2008, WILLIAM ANDREW INC
PHYSIOL REV, vol. 100, 2020, pages 1065 - 1075, Retrieved from the Internet <URL:https://journals.physiology.org/doi/pdf/10.1152/physrev.00013.2020>

Also Published As

Publication number Publication date
NO20200436A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
JP6387336B2 (en) Method and apparatus for detecting and treating heart failure
JP3696241B2 (en) Control of life support system
US20220079516A1 (en) Ultrasound-based closed-loop control of patient therapy
US7302295B2 (en) Method and apparatus for mimicking respiratory sinus arrhythmia with cardiac pacing controlled via external respiration therapy device
CN107205675B (en) Systems, devices, and methods for sensing physiological data and draining and analyzing bodily fluids
JP5235014B2 (en) Equipment for lymphatic system monitoring
US5315995A (en) Method and apparatus for continuous measurement of central venous oxygen saturation during human cardiopulmonary resuscitation and clinical shock
JP2022532375A (en) Systems and methods for detection and stimulation
JP2005526552A (en) Use of aortic pulse pressure and blood flow in clinical hemodynamic management
KR20040068136A (en) Device and procedure to treat cardiac atrial arrhythmias
Street Introduction to Biomedical Engineering Technology: Health Technology Management
RU2378983C1 (en) System of control over state and recovery of human organism vital functions
WO2021205214A1 (en) System for the removal of alveolar (thorax) fluids in patients with infectious and/or virus diseases (covid-19)
US6682481B2 (en) Resuscitation from shock
US20100094177A1 (en) Systems and methods for synchronizing ultrasound treatment of thryoid and parathyroid with movements of patients
Rincon Bedside transcranial sonography: A promising tool for the neurointensivist
Webster Biomedical instrumentation
Kumar A STUDY OF MECHANICAL VENTILATION ON CARDIOVASCULAR OUTPUT
CA2988433A1 (en) Enhancement of vasodilatory function and lowering of effective systemic vascular resistance
Webster Biomedical Instrumentation: Diagnosis and Therapy
US20210236018A1 (en) Method for monitoring lung integrity
Marshall CEREBRAL BLOOD FLOW DURING CARDIOPULMONARY RESUSCITATION
Araj et al. Letter by Araj and Hackmann Regarding Article,“Liberation From Venoarterial Extracorporeal Membrane Oxygenation: A Review”
SU1584905A1 (en) Method of diagnosis of cardiac insufficiency
Chizeck Adaptive control theory and applications to drug delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20719744

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 20.02.2023)

122 Ep: pct application non-entry in european phase

Ref document number: 20719744

Country of ref document: EP

Kind code of ref document: A1